Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients

NCT00822783 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

Medical University of Vienna